Kryzhanovskaya et al studied olanzapine versus placebo in adolescents with EOS.17 Compared with placebo-treated patients, olanzapine-treated adolescents had significant better results for the total score on the Brief Psychiatric Rating Scale for Children (BPRS-C), Clinical Global Impression Scale-Severity of Illness (CGI-S), and the PANSS total and positive scores. A secondary measure was patient response rates, defined a priori as a 30% or greater reduction of the BPRS-C total score from baseline to endpoint and a CGI-S score of 3 or lower on the final assessment. The a priori-defined response rate did not differ between the olanzapine and placebo groups (37.5% versus 25.7%); additionally, extrapyramidal symptoms did not differ between the groups.